Bristol-myers Squibb Compnay

Bayer Healthcare LLC

Bayer Pharmaceuticals Corporation

Bayer Intellectual Property Gmbh

Other

Uniroyal Chemical Company, Inc.

Crompton Gmbh

Viiv Healthcare UK (no.5) Limited

Bayer Pharma Aktiengesellschaft

Bristol-myers Squibb Holdings Ireland

Gan Wang

Makonen Belema

Omar D Lopez

Van N Nguyen

Nicholas A Meanwell

Jeffrey Lee Romine

Denis R St Laurent

Roger Astbury Smith

Lawrence B Snyder

Rico Lavoie

Lawrence G Hamann

Andrew Charles Good

Edward H Ruediger

David R Langley

Alain Martel

Carol Bachand

Daniel H Deon

Jason T Goodrich

Clint A James

Fukang Yang

John A Bender

Jacques P Dumas

Stephen J O'Connor

Wendy Lee

Piyasena Hewawasam

Ann-Marie Campbell

Mingbao Zhang

Lei Zhu

John F Kadow

Barton W Phillips

William Johnston Scott

Gaetan H Ladouceur

Alan Xiangdong Wang

Gerald J Abruscato

Brigitte Benage

Chengzhi Zhang

Annapurna Pendri

Mark George Saulnier

Wai C Wong

Robert G Gentles

Benjamin Jones

Soongyu Choi

Kyle E Parcella

Tatiana Shelekhin

David Bertil Frennesson

Xin Ma

Ning Miao Su

Zhong Yang

Derek B Lowe

Philip Coish

Miao Dai

Shihong Ying

Susan Jenkins

Zhi Chen

Ningning Xu

Qi Chen

Stephen Boyer

Qingjie Liu

Qingming Zhu

Sharad Verma

Jianqing Chen

Jennifer Burke

Karl Miranda

Furahi Achebe

Anthony Vincent Gentile

Holia Mokdad

Angela M Edwards

David Gunn

Mario Lobell

Yuanwei Chen

Yong Tu

Jianmei Fan

Manoranjan Panda

Brett R Beno

Srinivasan Thangathirupathy

Julie A Dixon

Hasibur Rahaman

Harold C E Kluender

Michael J Smith

Aniko Redman

Christiana I Iwuagwu

Rajesh Onkardas Bora

Selvakumar Kumaravel

Jesus R Fabian

Samayamunthula Venkata Satya Arun Kumar Gupta

Lin Yi

Stephan-Nicholas Wirtz

Andrea McClure

Lila Adnane

Robert A Fridell

Jianxing Shao

Mallikarjuna Rao Mettu

Brian Raudenbush

Vilen Vilan Kosover

Vilen Kosover

Derek Lowe

Roshan Yadavrao Nimje

Frederick Ehrgott

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C virus inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

Inhibitors of human immunodeficiency virus replication

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. 

Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A=pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g., cytotoxic therapies. 

Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders

This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer. 

Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases

The present invention relates to compounds of formula (I), pharmaceutical compositions which contain them and methods for treating cancer using compounds of formula (I). 

Substituted pyrazolyl urea derivatives useful in the treatment of cancer

Growing community of inventors

Wallingford, CT, United States of America

Gan Wang